CellChorus joins NVIDIA Inception

Program nurtures startups revolutionizing industries with advancements in artificial intelligence

PRESS RELEASE

HOUSTON, Texas — July 25, 2022 — CellChorus Inc. today announced it has joined NVIDIA Inception, a program designed to nurture startups revolutionizing industries with advancements in artificial intelligence (AI) and data sciences.

CellChorus® applies AI to visually evaluate thousands of microscopy experiments in parallel to understand how individual cells perform and interact over time. The company applies Time lapse Imaging Microscopy in Nanowell Grids™ (TIMING™) with neural network-based detection to identify which cells perform best—and why. CellChorus customers include leading developers and manufacturers of cell therapies and antibody therapeutics.

NVIDIA Inception will allow CellChorus to accelerate its growth into new therapeutic areas, geographies, and applications. The program will also offer CellChorus the opportunity to collaborate with industry-leading experts and other AI-driven organizations.

“As the leader in dynamic single-cell analysis, CellChorus is pioneering the next frontier of single-cell and multi-omic analysis for the life sciences industry,” said Daniel Meyer, CEO of CellChorus. “We are excited to join the NVIDIA Inception program. In addition to providing access to cutting-edge technology and experts, the program offers us unique opportunities to interact with innovators solving similar problems in other industries.”

NVIDIA Inception helps startups during critical stages of product development, prototyping and deployment. Every NVIDIA Inception member gets a custom set of ongoing benefits, such as NVIDIA Deep Learning Institute credits, marketing support, and technology assistance, which provides startups with the fundamental tools to help them grow.

About CellChorus

CellChorus® is the leader in applying artificial intelligence to quantify the function and performance of cells over time to improve the development and delivery of novel therapies that improve patient care. The company applies Time-lapse Imaging Microscopy In Nanowell Grids™ (TIMING™) with neural network-based detection to identify how cells move, activate, kill, and survive at single-cell resolution. The patent-protected platform can link TIMING data and insights with information from other analysis modalities such as single-cell RNA sequencing to provide a comprehensive understanding of cellular function, state and phenotype. Please visit cellchorus.com for more information.

Source: CellChorus Inc.

Company Contact:
Daniel Meyer
CellChorus Inc.
TIMING@cellchorus.com